Skip to main content
SpringerLink
Log in

Current status of CPT and its analogues in the treatment of malignancies

  • Published:
Phytochemistry Reviews Aims and scope Submit manuscript

Abstract

Camptothecin (CPT) is a kind of terpene indole alkaloid which was firstly isolated from native Chinese happy tree Camptotheca acuminata and owns a unique anti-tumor mechanism by inhibiting Topo I. Being approved by FDA, the camptothecin derivatives, irinotecan and topotecan, are extensively used for the treatment of various cancers throughout the world. In the past decades, pharmacology of CPT and its analogues has been well documented. This review will focus on different human malignancies with demonstrated clinical efficacy of CPT analogues.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  • Abou-Alfa GK, Letourneau R, Harker G et al (2006) Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 24:4441–4447

    CAS  PubMed  Google Scholar 

  • Ajani JA, Takimoto C, Becerra CR et al (2005) A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer. Invest New Drugs 23:479–484

    CAS  PubMed  Google Scholar 

  • Arakawa Y, Saito S, Yamada H et al (2009) Simultaneous treatment with camptothecin and valproic acid suppresses induction of Bcl-X(L) and promotes apoptosis of MCF-7 breast cancer cells. Apoptosis 14:1076–1085

    CAS  PubMed  Google Scholar 

  • Baka S, Agelaki S, Kotsakis A et al (2010) Phase III study comparing sequential versus alternate administration of cisplatin–etoposide and topotecan as first-line treatment in small cell lung cancer. Anticancer Res 30:3031–3038

    CAS  PubMed  Google Scholar 

  • Bastos BR, Hatoum GF, Walker GR et al (2010) Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung cancer. J Thorac Oncol 5:533–539

    PubMed  Google Scholar 

  • Bodurka DC, Levenback C, Wolf JK et al (2003) Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol 21:291–297

    PubMed  Google Scholar 

  • Bolis G, Scarfone G, Raspagliesi F et al (2010) Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III–IV epithelial ovarian cancer a multicenter, randomized study. Eur J Cancer 46:2905–2912

    CAS  PubMed  Google Scholar 

  • Brave M, Dagher R, Farrell A et al (2006) Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer. Oncology (Williston Park) 20:1401–1404

    Google Scholar 

  • Bryce AH, Mattar B, Hillman SL et al (2010) Phase II trial of oral topotecan and intravenous carboplatin with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: a North Central Cancer Treatment Group Study. Am J Clin Oncol 33:353–357

    CAS  PubMed  Google Scholar 

  • Burris HA 3rd, Rivkin S, Reynolds R et al (2005) Phase II trial of oral rubitecan in previously treated pancreatic cancer patients. Oncologist 10:183–190

    CAS  PubMed  Google Scholar 

  • Chang H, Kim SH, Cho BC et al (2012) Phase II study of cisplatin with irinotecan as induction chemotherapy followed by chemoradiotherapy for unresectable stage III non-small cell lung cancer. Anticancer Res 32:3515–3521

    CAS  PubMed  Google Scholar 

  • Charpidou A, Tsagouli S, Tsimpoukis S et al (2010) Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study. Anticancer Drugs 21:651–655

    CAS  PubMed  Google Scholar 

  • Chen G, Huynh M, Fehrenbacher L et al (2009) Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer. J Clin Oncol 27:1401–1404

    PubMed Central  CAS  PubMed  Google Scholar 

  • Chitapanarux I, Tonusin A, Sukthomya V et al (2003) Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer. Gynecol Oncol 89:402–407

    CAS  PubMed  Google Scholar 

  • Choi CH, Lee YY, Song TJ et al (2011) Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer. Cancer 117:2104–2111

    CAS  PubMed  Google Scholar 

  • Cichorek M, Kozlowska K, Bryl E (2007) The activity of caspases in spontaneous and camptothecin-induced death of melanotic and amelanotic melanoma cell. Cancer Biol Ther 6:346–353

    CAS  PubMed  Google Scholar 

  • Cirpanli Y, Allard E, Passirani C et al (2011) Antitumoral activity of camptothecin-loaded nanoparticles in 9L rat glioma model. Int J Pharm 403:201–206

    CAS  PubMed  Google Scholar 

  • Conti JA, Kemeny NE, Saltz LB et al (1996) Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14:709–715

    CAS  PubMed  Google Scholar 

  • Cormio G, Loizzi V, Gissi F et al (2011) Long-term topotecan therapy in recurrent or persistent ovarian cancer. Eur J Gynaecol Oncol 32:153–155

    CAS  PubMed  Google Scholar 

  • Coronel J, Cetina L, Candelaria M et al (2009) Weekly topotecan as second- or third-line treatment in patients with recurrent or metastatic cervical cancer. Med Oncol 26:210–214

    CAS  PubMed  Google Scholar 

  • Di Francesco AM, Riccardi A, Barone G et al (2005) The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: a comparative study with SN38 and topotecan. Biochem Pharmacol 70:1125–1136

    PubMed  Google Scholar 

  • Douillard JY, Cunningham D, Roth AD et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041–1047

    CAS  PubMed  Google Scholar 

  • Eckardt JR, von Pawel J, Pujol JL et al (2007) Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 25:2086–2092

    CAS  PubMed  Google Scholar 

  • El-Galley R, Keane TE, Sun C (2003) Camptothecin analogues and vinblastine in the treatment of renal cell carcinoma: an in vivo study using a human orthotopic renal cancer xenograft. Urol Oncol 21:49–57

    CAS  PubMed  Google Scholar 

  • Farhat FS (2007) A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer. Med Oncol 24:137–146

    CAS  PubMed  Google Scholar 

  • Fink TH, Huber RM, Heigener DF et al (2012) Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trial. J Thorac Oncol 7:1432–1439

    CAS  PubMed  Google Scholar 

  • Fujii T, Kunikane H, Okamoto H et al (2009) A phase II study of cisplatin and irinotecan as induction chemotherapy followed by accelerated hyperfractionated thoracic radiotherapy with daily low-dose carboplatin in unresectable stage III non-small cell lung cancer: JCOG 9510. Jpn J Clin Oncol 39:784–790

    PubMed  Google Scholar 

  • Fukuda M, Nakamura Y, Kinoshita A et al (2012) Phase II study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small cell lung cancer. Cancer Chemother Pharmacol 70:645–651

    CAS  PubMed  Google Scholar 

  • Ge XH, Lin Q, Ren XC et al (2013) Phase II clinical trial of whole-brain irradiation plus three-dimensional conformal boost with concurrent topotecan for brain metastases from lung cancer. Radiat Oncol 8:238

    PubMed Central  PubMed  Google Scholar 

  • Gonzalez EE, Villanueva N, Fra J et al (2011) Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: a phase II study. Invest New Drugs 29:1459–1464

    CAS  PubMed  Google Scholar 

  • Hariri G, Edwards AD, Merrill TB et al (2014) Sequential targeted delivery of paclitaxel and camptothecin using a cross-linked “nanosponge” network for lung cancer chemotherapy. Mol Pharm 11:265–275

    CAS  PubMed  Google Scholar 

  • Heinemann V, Hoff PM (2010) Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer. Oncology 79:118–128

    CAS  PubMed  Google Scholar 

  • Hiruma R, Kamide T, Anzai N et al (2008) Combined irinotecan (CPT-11) and nedaplatin (254-S) therapy for advanced and/or recurrent cervical cancer. Gan To Kagaku Ryoho 35:607–610

    CAS  PubMed  Google Scholar 

  • Hong J, Jung M, Kim YJ et al (2012) Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer. Cancer Chemother Pharmacol 69:215–220

    CAS  PubMed  Google Scholar 

  • Horn L, Zhao Z, Sandler A et al (2011) A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancer. Clin Lung Cancer 12:161–165

    CAS  PubMed  Google Scholar 

  • Hoskins P, Vergote I, Cervantes A et al (2010) Advanced ovarian cancer: phase III randomized study of sequential cisplatin–topotecan and carboplatin–paclitaxel vs carboplatin–paclitaxel. J Natl Cancer Inst 102:1547–1556

    CAS  PubMed  Google Scholar 

  • Hu Z, Guo X, Yu Q et al (2009) Down-regulation of adenine nucleotide translocase 3 and its role in camptothecin-induced apoptosis in human hepatoma QGY7703 cells. FEBS Lett 583:383–388

    CAS  PubMed  Google Scholar 

  • Hwang JH, Yoo HJ, Lim MC et al (2012) Phase I clinical trial of alternating belotecan and oral etoposide in patients with platinum-resistant or heavily treated ovarian cancer. Anticancer Drugs 23:321–325

    CAS  PubMed  Google Scholar 

  • James E, Waldron-Lynch MG, Saif MW (2009) Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. Anticancer Drugs 20:634–638

    CAS  PubMed  Google Scholar 

  • Jemal A, Center MM, DeSantis C et al (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomark Prev 19:1893–1907

    Google Scholar 

  • Jeong J, Cho BC, Sohn JH et al (2010) Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial. Lung Cancer 70:77–81

    PubMed  Google Scholar 

  • Kim HG, Lee GW, Kang JH et al (2008) Combination chemotherapy with irinotecan and cisplatin in elderly patients (> or =65 years) with extensive-disease small-cell lung cancer. Lung Cancer 61:220–226

    PubMed  Google Scholar 

  • Kim YY, Park CK, Kim SK et al (2009) CKD-602, a camptothecin derivative, inhibits proliferation and induces apoptosis in glioma cell lines. Oncol Rep 21:1413–1419

    CAS  PubMed  Google Scholar 

  • Kim HS, Park NH, Kang S et al (2010a) Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience. J Obstet Gynaecol Res 36:86–93

    CAS  PubMed  Google Scholar 

  • Kim SJ, Kim JS, Kim SC et al (2010b) A multicenter phase II study of belotecan, new camptothecin analogue, in patients with previously untreated extensive stage disease small cell lung cancer. Lung Cancer 68:446–449

    CAS  PubMed  Google Scholar 

  • Kim YM, Lee SW, Kim DY et al (2010c) The efficacy and toxicity of belotecan (CKD-602), a camptothericin analogue topoisomerase I inhibitor, in patients with recurrent or refractory epithelial ovarian cancer. J Chemother 22:197–200

    PubMed  Google Scholar 

  • Kim YS, Park SH, Kyung SY et al (2011) Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer. Med Oncol 28:342–350

    CAS  PubMed  Google Scholar 

  • Kim CY, Lee SJ, Kim SK et al (2012) Antitumor activity of CKD-602, a camptothecin derivative, in a mouse glioma model. J Clin Neurosci 19:301–305

    CAS  PubMed  Google Scholar 

  • Kim HS, Kim JH, Kim B et al (2013) Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 71:1591–1597

    CAS  PubMed  Google Scholar 

  • Kraut EH, Balcerzak SP, Young D et al (2000) A phase II study of 9-aminocamptothecin in patients with refractory breast cancer. Cancer Invest 18:28–31

    CAS  PubMed  Google Scholar 

  • Kurtzberg LS, Roth S, Krumbholz R et al (2011) Genz-644282, a novel non-camptothecin topoisomerase I inhibitor for cancer treatment. Clin Cancer Res 17:2777–2787

    CAS  PubMed  Google Scholar 

  • Lally BE, Urbanic JJ, Blackstock AW et al (2007) Small cell lung cancer: have we made any progress over the last 25 years? Oncologist 12:1096–1104

    PubMed  Google Scholar 

  • Lara PN Jr, Natale R, Crowley J et al (2009) Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 27:2530–2535

    PubMed Central  CAS  PubMed  Google Scholar 

  • Lee DH, Kim SW, Suh C et al (2008a) Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study. Ann Oncol 19:123–127

    CAS  PubMed  Google Scholar 

  • Lee HP, Seo SS, Ryu SY et al (2008b) Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer. Gynecol Oncol 109:359–363

    CAS  PubMed  Google Scholar 

  • Lee BS, Nalla AK, Stock IR et al (2010a) Oxidative stimuli-responsive nanoprodrug of camptothecin kills glioblastoma cells. Bioorg Med Chem Lett 20:5262–5268

    CAS  PubMed  Google Scholar 

  • Lee DH, Kim SW, Suh C et al (2010b) Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer. Cancer 116:132–136

    CAS  PubMed  Google Scholar 

  • Lee YY, Lee JW, Park HS et al (2010c) Sequence-dependent hematologic side effects of topotecan and cisplatin in persistent or recurrent cervical cancer. Gynecol Oncol 119:87–91

    CAS  PubMed  Google Scholar 

  • Li C, Huang XE, Li Y (2011) Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer. Asian Pac J Cancer Prev 12:487–490

    PubMed  Google Scholar 

  • Li Z, Li X, Cao Z et al (2012) Camptothecin nanocolloids based on N,N,N-trimethyl chitosan: efficient suppression of growth of multiple myeloma in a murine model. Oncol Rep 27:1035–1040

    PubMed Central  CAS  PubMed  Google Scholar 

  • Lim S, Cho BC, Jung JY et al (2013) Phase II study of camtobell inj. (belotecan) in combination with cisplatin in patients with previously untreated, extensive stage small cell lung cancer. Lung Cancer 80:313–318

    PubMed  Google Scholar 

  • Liu W, Zhu YS, Guo M et al (2007) Therapeutic efficacy of NSC606985, a novel camptothecin analog, in a mouse model of acute promyelocytic leukemia. Leuk Res 31:1565–1574

    CAS  PubMed  Google Scholar 

  • Liu S, Yuan Y, Okumura Y et al (2010a) Camptothecin disrupts androgen receptor signaling and suppresses prostate cancer cell growth. Biochem Biophys Res Commun 394:297–302

    CAS  PubMed  Google Scholar 

  • Liu XP, Zhou ST, Li XY et al (2010b) Anti-tumor activity of N-trimethyl chitosan-encapsulated camptothecin in a mouse melanoma model. J Exp Clin Cancer Res 29:76

    PubMed Central  PubMed  Google Scholar 

  • Long HJ 3rd, Bundy BN, Grendys EC et al (2005) Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 23:4626–4633

    CAS  PubMed  Google Scholar 

  • Lorusso D, Mainenti S, Pietragalla A et al (2011) Phase II study on weekly bolus topotecan in advanced or recurrent cervical cancer. Oncology 80:390–394

    CAS  PubMed  Google Scholar 

  • Machida S, Ohwada M, Fujiwara H et al (2003) Phase I study of combination chemotherapy using irinotecan hydrochloride and nedaplatin for advanced or recurrent cervical cancer. Oncology 65:102–107

    CAS  PubMed  Google Scholar 

  • Matsumoto K, Katsumata N, Yamanaka Y et al (2006) The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer. Gynecol Oncol 100:412–416

    CAS  PubMed  Google Scholar 

  • McGuire WP, Hoskins WJ, Brady MF et al (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1–6

    CAS  PubMed  Google Scholar 

  • Minelli R, Cavalli R, Ellis L et al (2012) Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells. Eur J Pharm Sci 47:686–694

    CAS  PubMed  Google Scholar 

  • Misumi Y, Nishio M, Takahashi T et al (2014) A feasibility study of carboplatin plus irinotecan treatment for elderly patients with extensive disease small-cell lung cancer. Jpn J Clin Oncol 44:116–121

    PubMed  Google Scholar 

  • Murata Y, Hirose T, Yamaoka T et al (2011) Phase II trial of the combination of carboplatin and irinotecan in elderly patients with small-cell lung cancer. Eur J Cancer 47:1336–1342

    CAS  PubMed  Google Scholar 

  • Nam EJ, Kim JW, Kim JH et al (2010) Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer. Am J Clin Oncol 33:233–237

    CAS  PubMed  Google Scholar 

  • Niitsu N, Iijima K, Chizuka A (2001) Combination therapy with irinotecan (CPT-11), mitoxantrone, and dexamethasone in relapsed or refractory non-Hodgkin’s lymphoma: a pilot study. Ann Hematol 80:411–416

    CAS  PubMed  Google Scholar 

  • Nishio S, Sugiyama T, Shouji T et al (2007) Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum- and taxane-resistant epithelial ovarian cancer. Gynecol Oncol 106:342–347

    CAS  PubMed  Google Scholar 

  • Noda K, Nishiwaki Y, Kawahara M et al (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85–91

    CAS  PubMed  Google Scholar 

  • Noro R, Yoshimura A, Yamamoto K et al (2013) Alternating chemotherapy with amrubicin plus cisplatin and weekly administration of irinotecan plus cisplatin for extensive-stage small cell lung cancer. Anticancer Res 33:1117–1123

    CAS  PubMed  Google Scholar 

  • Numbenjapon T, Wang J, Colcher D et al (2009) Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models. Clin Cancer Res 15:4365–4373

    PubMed Central  CAS  PubMed  Google Scholar 

  • O’Brien ME, Ciuleanu TE, Tsekov H et al (2006) Phase III trial comparing supportive care alone with supportive care with oral topotecan inpatients with relapsed small-cell lung cancer. J Clin Oncol 24:5441–5447

    PubMed  Google Scholar 

  • Ohara T, Kobayashi Y, Yoshida A et al (2013) Combination of irinotecan (CPT-11) and nedaplatin (NDP) for recurrent patients with uterine cervical cancer. Int J Clin Oncol 18:1102–1106

    CAS  PubMed  Google Scholar 

  • Ohe M, Oshita F, Kenmotsu Y et al (2012) Nedaplatin and irinotecan for patients with recurrent small cell lung cancer. J Exp Ther Oncol 10:65–69

    CAS  PubMed  Google Scholar 

  • Okishio K, Mio T, Kawahara M et al (2012) A weekly combination of carboplatin and irinotecan for previously untreated extensive disease small-cell lung cancer, results of a minimum follow-up of 3 years: a multi-center Phase II trial JMTO LC02-02. Jpn J Clin Oncol 42:387–393

    PubMed  Google Scholar 

  • Oshita F, Sugiura M, Murakami S et al (2013) Phase II study of nedaplatin and irinotecan in patients with extensive small-cell lung cancer. Cancer Chemother Pharmacol 71:345–350

    CAS  PubMed  Google Scholar 

  • Papadimitriou CA, Papakostas P, Karina M et al (2011) A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study. BMC Med 9:10

    PubMed Central  CAS  PubMed  Google Scholar 

  • Parra E, Ferreira J (2010) The effect of siRNA-Egr-1 and camptothecin on growth and chemosensitivity of breast cancer cell lines. Oncol Rep 23:1159–1165

    CAS  PubMed  Google Scholar 

  • Polyzos A, Kosmas C, Toufexi H et al (2005) Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclitaxel-pretreated ovarian cancer. Anticancer Res 25:3559–3564

    CAS  PubMed  Google Scholar 

  • Pratesi G, De Cesare M, Carenini N et al (2002) Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts. Clin Cancer Res 8:3904–3909

    CAS  PubMed  Google Scholar 

  • Qi WX, Shen Z, Lin F et al (2013) Overall survival benefits for irinotecan-containing regimens as first-line treatment for advanced gastric cancer: an updated meta-analysis of ten randomized controlled trials. Int J Cancer 132:E66–E73

    CAS  PubMed  Google Scholar 

  • Quintas-Cardama A, Kantarjian H, O’Brien S et al (2006) Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. Cancer 107:1525–1529

    CAS  PubMed  Google Scholar 

  • Ramasubbaiah R, Perkins SM, Schilder J et al (2011) Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group. Gynecol Oncol 123:499–504

    CAS  PubMed  Google Scholar 

  • Raspagliesi F, Ditto A, Selvaggi L et al (2010) A phase 2 multicenter study of irinotecan and cisplatinum as neoadjuvant treatment in patients with locally advanced cervical cancer. Int J Gynecol Cancer 20:1569–1575

    PubMed  Google Scholar 

  • Reinicke KE, Kuffel MJ, Goetz MP et al (2010) Synergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast cancer cells. Cancer Chemother Pharmacol 66:575–583

    PubMed Central  CAS  PubMed  Google Scholar 

  • Ren Y, Li Y, Liu J (2011) A modified shortened administration schedule for neoadjuvant chemotherapy with irinotecan and cisplatin in locally advanced cervical cancer. Int J Gynecol Cancer 21:685–689

    PubMed  Google Scholar 

  • Rhee CK, Lee SH, Kim JS et al (2011) A multicenter phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancer. Lung Cancer 72:64–67

    PubMed  Google Scholar 

  • Rougier P, Bugat R, Douillard JY et al (1997) Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15:251–260

    CAS  PubMed  Google Scholar 

  • Rudolf E, Rudolf K, Cervinka M (2011) Camptothecin induces p53-dependent and -independent apoptogenic signaling in melanoma cells. Apoptosis 16:1165–1176

    CAS  PubMed  Google Scholar 

  • Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905–914

    CAS  PubMed  Google Scholar 

  • Saotome T, Takagi T, Sakai C et al (2000) Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin’s lymphoma. Ann Oncol 11:115–116

    CAS  PubMed  Google Scholar 

  • Schluep T, Hwang J, Cheng J et al (2006) Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res 12:1606–1614

    CAS  PubMed  Google Scholar 

  • Schmittel A, Sebastian M, Fischer von Weikersthal L et al (2011) A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide–carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol 22:1798–1804

    CAS  PubMed  Google Scholar 

  • Scott LC, Yao JC, Benson AB 3rd et al (2009) A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemother Pharmacol 63:363–370

    CAS  PubMed  Google Scholar 

  • Sehouli J, Stengel D, Harter P et al (2011) Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 29:242–248

    CAS  PubMed  Google Scholar 

  • Seung SK, Ross HJ (2009) Phase II trial of combined modality therapy with concurrent topotecan plus radiotherapy followed by consolidation chemotherapy for unresectable stage III and selected stage IV non-small-lung cancer. Int J Radiat Oncol Biol Phys 73:802–809

    CAS  PubMed  Google Scholar 

  • Shimada Y, Yoshino M, Wakui A et al (1993) Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 11:909–913

    CAS  PubMed  Google Scholar 

  • Shoji T, Takatori E, Hatayama S et al (2010) Phase II study of tri-weekly cisplatin and irinotecan as neoadjuvant chemotherapy for locally advanced cervical cancer. Oncol Lett 1:515–519

    PubMed Central  CAS  PubMed  Google Scholar 

  • Shoji T, Takatori E, Omi H, Kumagai S et al (2011) Phase II clinical study of the combination chemotherapy regimen of irinotecan plus oral etoposide for the treatment of recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 101 Group Study). Int J Gynecol Cancer 21:44–50

    PubMed  Google Scholar 

  • Spigel DR, Greco FA, Zubkus JD et al (2009) Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer. J Thorac Oncol 4:1555–1560

    PubMed  Google Scholar 

  • Spigel DR, Hainsworth JD, Gandhi JG et al (2010) A phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung cancer. J Thorac Oncol 5:862–866

    PubMed  Google Scholar 

  • Stein SM, Tiersten A, Hochster HS et al (2013) A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancer. Int J Gynecol Cancer 23:1577–1582

    PubMed  Google Scholar 

  • Sugiyama T, Yakushiji M, Nishida T et al (1998) Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer. Cancer Lett 128:211–218

    CAS  PubMed  Google Scholar 

  • Sugiyama T, Nishida T, Kumagai S et al (1999) Combination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer. Br J Cancer 81:95–98

    PubMed Central  CAS  PubMed  Google Scholar 

  • Sugiyama T, Yakushiji M, Noda K et al (2000) Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer. Oncology 58:31–37

    CAS  PubMed  Google Scholar 

  • Sugiyama T, Yakushiji M, Kamura T et al (2002) Irinotecan (CPT-11) and cisplatin as first-line chemotherapy for advanced ovarian cancer. Oncology 63:16–22

    CAS  PubMed  Google Scholar 

  • Suntornpong N, Pattaranutaporn P, Chanslip Y et al (2003) Concurrent radiation therapy and irinotecan in stage IIIB cervical cancer. J Med Assoc Thai 86:430–435

    PubMed  Google Scholar 

  • Suprasert P, Charoenkwan K, Cheewakriangkrai C (2010) Outcomes of advanced and recurrent cervical cancer treated with cisplatin and generic topotecan: retrospective analysis in a tertiary care hospital in Thailand. J Gynecol Oncol 21:237–240

    PubMed Central  CAS  PubMed  Google Scholar 

  • Suzuki H, Hirashima T, Kobayashi M et al (2011) Effect of topotecan as second-line chemotherapy for small cell lung cancer patients with interstitial lung disease. J Chemother 23:367–370

    CAS  PubMed  Google Scholar 

  • Takeda K, Negoro S, Tanaka M et al (2011) A phase II study of cisplatin and irinotecan as induction chemotherapy followed by concomitant thoracic radiotherapy with weekly low-dose irinotecan in unresectable, stage III, non-small cell lung cancer: JCOG 9706. Jpn J Clin Oncol 41:25–31

    PubMed  Google Scholar 

  • Tan C, Cai LQ, Wu W et al (2009) NSC606985, a novel camptothecin analog, induces apoptosis and growth arrest in prostate tumor cells. Cancer Chemother Pharmacol 63:303–312

    PubMed Central  CAS  PubMed  Google Scholar 

  • Tsuda H, Hashiguchi Y, Nishimura S et al (2004) Phase I–II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer. Br J Cancer 91:1032–1037

    PubMed Central  CAS  PubMed  Google Scholar 

  • Ulivi P, Zoli W, Fabbri F et al (2005) Cellular basis of antiproliferative and antitumor activity of the novel camptothecin derivative, gimatecan, in bladder carcinoma models. Neoplasia 7:152–161

    PubMed Central  CAS  PubMed  Google Scholar 

  • Ushijima K, Kamura T, Tamura K et al (2013) Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study. Int J Clin Oncol 18:126–131

    CAS  PubMed  Google Scholar 

  • Van Cutsem E, Labianca R, Bodoky G et al (2009) Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 27:3117–3125

    PubMed  Google Scholar 

  • von Pawel J, Schiller JH, Shepherd FA et al (1999) Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17:658–667

    Google Scholar 

  • Wahba HA, Halim AA, El-Hadaad HA (2012) Irinotecan plus cisplatin chemotherapy followed by concurrent thoracic irradiation with low-dose weekly cisplatin for limited-disease small-cell lung cancer. Med Oncol 29:199–204

    CAS  PubMed  Google Scholar 

  • Weiss GJ, Chao J, Neidhart JD et al (2013) First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. Invest New Drugs 31:986–1000

    PubMed Central  CAS  PubMed  Google Scholar 

  • Xenidis N, Kotsakis A, Kalykaki A et al (2010) Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: a multicenter phase II study. Lung Cancer 68:450–454

    CAS  PubMed  Google Scholar 

  • Xiong Y, Liang LZ, Cao LP et al (2011) Clinical effects of irinotecan hydrochloride in combination with cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer. Gynecol Oncol 123:99–104

    CAS  PubMed  Google Scholar 

  • Yahagi N, Kobayashi Y, Ohara T et al (2009) Usefulness of clinical study of irinotecan and cisplatin for recurrent ovarian cancer. Gan To Kagaku Ryoho 36:2583–2586

    PubMed  Google Scholar 

  • Yoshimura A, Noro R, Miyanaga A et al (2012) Combination chemotherapy of alternating etoposide and carboplatin with weekly administration of irinotecan and cisplatin in extensive-stage small-cell lung cancer. Anticancer Res 32:4473–4478

    CAS  PubMed  Google Scholar 

  • Zarogoulidis K, Mylonaki E, Kakavelas P et al (2009) Topotecan-carboplatin–etoposide combination as 1st line treatment in patients with small cell lung cancer. Lung Cancer 66:226–230

    CAS  PubMed  Google Scholar 

  • Zatloukal P, Cardenal F, Szczesna A et al (2010) A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol 21:1810–1816

    CAS  PubMed  Google Scholar 

  • Zhang X, Gan Y, Gan L et al (2008) PEGylated nanostructured lipid carriers loaded with 10-hydroxycamptothecin: an efficient carrier with enhanced anti-tumour effects against lung cancer. J Pharm Pharmacol 60:1077–1087

    CAS  PubMed  Google Scholar 

  • Zhang H, Jia L, Xu Y et al (2012) Topotecan plus carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a meta-analysis of randomized controlled trials. J Chemother 24:67–73

    PubMed  Google Scholar 

  • Zhang H, Wang X, Dai W et al (2014) Pharmacokinetics and treatment efficacy of camptothecin nanocrystals on lung metastasis. Mol Pharm 11:226–233

    CAS  PubMed  Google Scholar 

  • Zhou L, Li X, Chen X et al (2010) In vivo antitumor and antimetastatic activities of camptothecin encapsulated with N-trimethyl chitosan in a preclinical mouse model of liver cancer. Cancer Lett 297:56–64

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors are grateful for financial sponsored by the Shanghai Committee of Science and Technology, China (13140902402).

Conflict of interest

The authors confirm that this article content has no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China

    Guohua Hu, David Zekria & Xiaoling Ni

  2. Shanghai Institute of Hematology and State Key Laboratory of Medical Genomics, Rui-jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China

    Xun Cai

Authors
  1. Guohua Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Zekria
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xun Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiaoling Ni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Xun Cai or Xiaoling Ni.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hu, G., Zekria, D., Cai, X. et al. Current status of CPT and its analogues in the treatment of malignancies. Phytochem Rev 14, 429–441 (2015). https://doi.org/10.1007/s11101-015-9397-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11101-015-9397-1

Keywords

Search

Navigation